Whalesbook
Valuation Under Scrutiny
Divi's Laboratories, known for its high valuation in India's pharmaceutical sector with a trailing P/E ratio near 72x, faced a market reaction that signals a shift in investor focus. While the company achieved its highest-ever quarterly net profit, the negative response suggests that sustained growth alone is insufficient. Investors are now closely watching the company's ability to maintain operating margins against fluctuating energy and feedstock prices, which are key to justifying its premium stock price.
Rising Input Costs Impact Margins
The drop in EBITDA margins reflects a wider trend affecting chemical and pharmaceutical manufacturers. Global geopolitical issues are driving up crude oil and energy prices, which in turn increases the cost of petrochemical-based raw materials essential for APIs. Although Divi's maintains a strong financial position with no long-term debt, rising external costs are beginning to affect even efficient producers. The 100 basis point decline in operating margins serves as a caution, indicating that Divi's must effectively pass these increased costs to its clients to avoid volatile margin performance.
Risks for a High-Priced Stock
From a conservative viewpoint, the current valuation of Divi's stock offers little room for operational missteps. A key concern is whether its high-margin contract development and manufacturing (CDMO) business can sufficiently offset declining prices in its generic API segment. The company's significant export focus, while providing a natural currency hedge, also exposes it to strict global regulatory oversight and evolving environmental, social, and governance (ESG) standards. These factors add to operational expenses. Divi's large-scale infrastructure requires high capacity utilization to maintain its return on capital employed (ROCE). Any slowdown in global pharmaceutical demand or changes in Big Pharma's outsourcing strategies could lead to a decrease in its earnings multiple.
Looking Ahead
Despite current margin pressures, analysts remain optimistic about Divi's long-term prospects, particularly its role in supplying intermediates for GLP-1 drugs and contrast media. The record revenue of ₹10,560 crore in FY26 confirms the strength of its CDMO services. For the current fiscal year, success in managing raw material cost volatility through supply chain diversification and maintaining a revenue growth rate of 15-20% will be crucial. The company's substantial dividend declaration indicates confidence in its financial health, but the stock is currently facing a market test of its valuation against operational realities.